Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform.

1. The construction of a three-dimensional model of human CYP2E1 is reported. It is based on homology with the haemoprotein domain of the unusual bacterial P450, CYP102, which is of known crystal structure. 2. Interactive docking of a number of human CYP2E1 substrates is consistent with their known positions of CYP2E1-mediated metabolism, where specific interactions with key active site amino acid side-chains appear to rationalize the binding and orientation of substrate molecules. 3. Amino acid residues within the putative active site of human CYP2E1, including those associated with the binding of substrates and inhibitors, are shown to correspond with those identified by site-directed mutagenesis experiments conducted on CYP2 family isoforms, and they are known to affect substrate metabolism regioselectivity. 4. Consequently, it was found that the CYP2E1 active site exhibits complementarity with the structural characteristics of known substrates and inhibitors of this enzyme, including their relatively low molecular weights and disposition of hydrogen bond-forming groups.

[1]  M H Tarbit,et al.  Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. , 1998, Chemico-biological interactions.

[2]  D. Lewis,et al.  Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. , 1998, Mutation research.

[3]  S. French,et al.  P-450-dependent metabolism of lauric acid in alcoholic liver disease: comparison between rat liver and kidney microsomes. , 1998, Alcoholism, clinical and experimental research.

[4]  F. Guengerich,et al.  Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. , 1997, Biochemistry.

[5]  Dennis A. Smith,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .

[6]  D. Lewis,et al.  Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. , 1997, Toxicology.

[7]  C. S. Yang,et al.  A hypothetical model for the active site of human cytochrome P4502E1. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[9]  T. Poulos,et al.  The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid , 1997, Nature Structural Biology.

[10]  J. Falck,et al.  An Active Site Substitution, F87V, Converts Cytochrome P450 BM-3 into a Regio- and Stereoselective (14S,15R)-Arachidonic Acid Epoxygenase* , 1997, The Journal of Biological Chemistry.

[11]  F. Gonzalez,et al.  Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[13]  C. Waller,et al.  Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[14]  P. Ortiz de Montellano,et al.  Active site topology of human cytochrome P450 2E1. , 1996, Chemical research in toxicology.

[15]  A. Parkinson An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.

[16]  Jeffrey P. Jones,et al.  Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Dreisbach,et al.  Urinary excretion of 6‐hydroxychlorzoxazone as an index of CYP2E1 activity , 1995, Clinical pharmacology and therapeutics.

[18]  Ta-Liang Chen,et al.  Human cytochrome P450 mono-oxygenase system is suppressed by propofol , 1995 .

[19]  D. Lewis Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  D. Wade,et al.  Probing the active sites of rat and human cytochrome P450 2E1 with alcohols and carboxylic acids. , 1995, Archives of biochemistry and biophysics.

[21]  R. Melnick,et al.  Mechanistic data indicate that 1,3-butadiene is a human carcinogen. , 1995, Carcinogenesis.

[22]  J. A. Bond,et al.  Epidemiological and mechanistic data suggest that 1,3-butadiene will not be carcinogenic to humans at exposures likely to be encountered in the environment or workplace. , 1995, Carcinogenesis.

[23]  Ardies Cm,et al.  Effect of swimming exercise and ethanol on rat liver P450-dependent monooxygenases. , 1994 .

[24]  D. Parke,et al.  The cytochromes P450 and mechanisms of chemical carcinogenesis. , 1994, Environmental health perspectives.

[25]  A. Cederbaum,et al.  DNA strand cleavage as a sensitive assay for the production of hydroxyl radicals by microsomes: role of cytochrome P4502E1 in the increased activity after ethanol treatment. , 1994, The Biochemical journal.

[26]  D. Smith,et al.  Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[27]  Dennis A. Smith Chemistry and enzymology: Their use in the prediction of human drug metabolism , 1994 .

[28]  W. Dekant,et al.  Gas-uptake pharmacokinetics of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123). , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[29]  A. Elfarra,et al.  Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. , 1994, Archives of biochemistry and biophysics.

[30]  T. Porter,et al.  Mutagenesis at a highly conserved phenylalanine in cytochrome P450 2E1 affects heme incorporation and catalytic activity. , 1994, Biochemistry.

[31]  D. Lewis,et al.  Interaction of a series of nitriles with the alcohol-inducible isoform of P450: computer analysis of structure-activity relationships. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  C. Ioannides,et al.  Modulation of the rat hepatic cytochrome P450 composition by long-term streptozotocin-induced insulin-dependent diabetes. , 1994, Journal of biochemical toxicology.

[33]  W. Dekant,et al.  Metabolism of the chlorofluorocarbon substitute 1,1-dichloro-2,2,2-trifluoroethane by rat and human liver microsomes: the role of cytochrome P450 2E1. , 1994, Chemical research in toxicology.

[34]  J. Miners,et al.  Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. , 1993, Biochemical pharmacology.

[35]  W. Lijinsky Life-span and cancer: the induction time of tumors in diverse animal species treated with nitrosodiethylamine. , 1993, Carcinogenesis.

[36]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[37]  D. Koop,et al.  Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. , 1993, The Journal of biological chemistry.

[38]  H. Vainio,et al.  Cytochrome P450-related differences between rats and mice in the metabolism of benzene, toluene and trichloroethylene in liver microsomes. , 1993, Biochemical pharmacology.

[39]  C. Ioannides,et al.  Effects of ether anaesthesia and fasting on various cytochromes P450 of rat liver and kidney. , 1993, Biochemical pharmacology.

[40]  J. A. Bond,et al.  Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. , 1992, Carcinogenesis.

[41]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[42]  D. Koop Oxidative and reductive metabolism by cytochrome P450 2E1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  C. S. Yang,et al.  Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. , 1991, Chemical research in toxicology.

[44]  F. Guengerich,et al.  Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.

[45]  S. Nelson Molecular Mechanisms of the Hepatotoxicity Caused by Acetaminophen , 1990, Seminars in liver disease.

[46]  D. Lewis,et al.  Role of hepatic and renal cytochrome P-450 IVA1 in the metabolism of lipid substrates. , 1989, Biochemical pharmacology.

[47]  J. Sangster,et al.  Octanol‐Water Partition Coefficients of Simple Organic Compounds , 1989 .

[48]  C. Lieber,et al.  Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. , 1989, Archives of biochemistry and biophysics.

[49]  M. Levitt,et al.  Aromatic Rings Act as Hydrogen Bond Acceptors , 2022 .

[50]  Feng Xu,et al.  Model reactions related to cytochrome P-450. Effects of alkene structure on the rates of epoxide formation , 1988 .

[51]  B. Rodrigues,et al.  Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. , 1988, Molecular pharmacology.

[52]  A. Cederbaum,et al.  Microsomal Generation of Hydroxyl Radicals: Its Role in Microsomal Ethanol Oxidizing System (MEOS) Activity and Requirement for Iron a , 1987, Annals of the New York Academy of Sciences.

[53]  J. G. Vinter,et al.  Strategic approaches to drug design. I. An integrated software framework for molecular modelling , 1987, J. Comput. Aided Mol. Des..

[54]  L. Narhi,et al.  Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium. , 1986, The Journal of biological chemistry.

[55]  M. Ingelman-Sundberg,et al.  Hydroxylation of acetone by ethanol‐ and acetone‐inducible cytochrome P‐450 in liver microsomes and reconstituted membranes , 1986, FEBS letters.

[56]  M. Ingelman-Sundberg,et al.  Hydroxyl-radical production and ethanol oxidation by liver microsomes isolated from ethanol-treated rats. , 1986, The Biochemical journal.

[57]  J. Casazza,et al.  Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. , 1985, The Journal of biological chemistry.

[58]  H. Glatt,et al.  Drug metabolism in man and its relationship to that in three rodent species: monooxygenase, epoxide hydrolase, and glutathione S-transferase activities in subcellular fractions of lung and liver. , 1984, Biochemical medicine.

[59]  M. J. Coon,et al.  Purification and characterization of a unique isozyme of cytochrome P-450 from liver microsomes of ethanol-treated rabbits. , 1982, The Journal of biological chemistry.

[60]  D. Lewis,et al.  The CYP2 family: models, mutants and interactions. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[61]  C. Ioannides,et al.  Nitrosamine carcinogenesis: rodent assays, quantitative structure-activity relationships, and human risk assessment. , 1997, Drug metabolism reviews.

[62]  D. Lewis,et al.  Cytochromes P450: structure, function and mechanism. , 1996 .

[63]  B. Halliwell,et al.  Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. , 1996, The Biochemical journal.

[64]  F. Gonzalez,et al.  Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. , 1994, Drug metabolism reviews.

[65]  M. Komori,et al.  Replacement of Thr-303 of P450 2E1 with serine modifies the regioselectivity of its fatty acid hydroxylase activity. , 1993, Journal of biochemistry.

[66]  J. Kraner,et al.  Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. , 1993, Critical reviews in toxicology.

[67]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[68]  Aleksandar Sabljic,et al.  Predicting the night-time NO3 radical reactivity in the troposphere , 1990 .

[69]  B. Halliwell,et al.  Role of free radicals and catalytic metal ions in human disease: an overview. , 1990, Methods in enzymology.

[70]  C. S. Yang,et al.  Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. , 1990, Drug metabolism reviews.

[71]  D. F. Lewis Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P-450-mediated aniline hydroxylation. , 1987, Chemico-biological interactions.